Avon Launches ‘Kiss Goodbye to Breast Cancer’ Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

NEW YORK-This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

NEW YORK—This month Avon Products, Inc. launches Kiss Goodbye to Breast Cancer, a marketing program that includes a fundraising lipstick, grassroots outreach through a Day of Commitment (September 25), gala awards to be held October 9, and celebrity support from singer Christina Aguilera and tennis players Serena and Venus Williams, among others.

The goal of the program is to raise additional funds and public awareness for the fight against breast cancer, building on the more than $140 million that Avon has already raised globally between 1992 to the end of 2000.

The lipsticks, priced at an affordable $4.00, include six shades in the Avon Ultra Color Rich Renewable formulation, named to capture the spirit of the crusade: Courageous Spirit, Crusade Pink, Faithful Heart, Inspirational Life, Strength, and Triumph.

The entire Avon Breast Cancer Crusade "pink ribbon" collection is available through Avon independent sales representatives by calling 1-800-FOR-AVON or visiting www.avoncrusade.com.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content